530 Background: There is considerable evidence that aromatase inhibitors are superior to T as first line endocrine therapy for metastatic disease. E an aromatase inactivator, is effective in women whose tumor has progressed despite T therapy. Methods: 151 PM women with ER+ breast cancer (BC) were randomly assigned once-daily treatment with either E alone 25 mg (n=76), or T alone (n=75) for 3 months. The primary endpoint was clinical objective response (OR). Secondary endpoints were OR determined by mammography and ultrasound, and number of pts who underwent breast conserving surgery (BCS). Result: Clinical, mammography, BCS rate are shown in the table. A pathological CR was shown in two pts in the E group and 2 pts in the T group. Response to any type of endocrine treatment was more likely in pts with higher levels of ER expression. Median time to response was 57 days in the E group and 70 days in the T group (p0.05). 3-year disease free survival rates were 78.9% in E group and 74.6% in T group (p>0.05). Conclusion: E is more effective than T as neoadjuvant therapy for PM pts with ER+ tumors in rate of clinical OR and BCS. No significant financial relationships to disclose.
8 June 2020 in Tumors of female reproductive system
Biopsy of signal (sentinel) lymph nodes (LN) has been performed at the N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia, for almost 20 years. In the first few years, contrast-visual method (1 % blue isosulfan and triphenyl methane control) was used in 640 patients with early (T1–2N0M0) breast cancer. In 150 patients from this cohort, standard axillary dissection was performed irrespectively of the results of signal (sentinel) biopsy. The rate of false positive responses varied between 4.6 and 6.6 %. Since 2012, radioisotope method of visualization of signal LN with intratumor administration of 99mТс-technephyte colloid particles has been used (in 708 patients with T1–3N0M0 breast cancer). This type of signal LN biopsy had the following diagnostic characteristics: sensitivity was 58.9 %, specificity was 96.2 %, diagnostic accuracy was 87.1 %.In parallel with this study, in 2016 a study of diagnostic accuracy and safety of biopsy of axillary LN after neoadjuvant systemic therapy was started. The study included 263 patients with T1N1–3M0, T2–3N0–3M0, T4N0–1M0 breast cancer. To evaluate clinical status of axillary LN, ultrasound, single-photon emission computed tomography, mammography at baseline and after completion of neoadjuvant chemotherapy ± targeted therapy (trastuzumab) were performed. In some patients, in the recent years a double method of signal LN labeling (radioisotope and fluorescent methods) was used.In patients with baseline cN+-status, the rate of false positive signal LN biopsy conclusions was 13.6 %, in patients with baseline cN0-status it was 7.7 %.The study of double contrast of axillary LN and targeted label of metastatic LN prior to neoadjuvant systemic therapy continues. In total, various modifications of biopsy of signal LN were performed in 2,000 patients with breast cancer.The study protocol was approved by the biomedical ethics committee of N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia.All patients gave written informed consent to participate in the study.
Materials and methods. The effect of melatonin (MLT) and metformin (MTF) on the efficacy of neoadjuvant hormone therapy with toremifene was investigated in 54 patients with estrogen receptor-positive, locally advanced breast cancer (ER + BC). The average age of women was 67 years. The patients had no diabetes mellitus. The first group of patients (n = 19) received toremifene 120 mg per day, the second group (n = 16) - toremifene in combination with MLT 3 mg orally every night, the third group (n = 19) - toremifene in combination with MTF 850 mg twice daily. Randomization was performed - 1: 1: 1. The duration of therapy in all study groups was 4 months. After the end of treatment, all patients were undergone surgery. Further adjuvant treatment depended on the results of the postoperative pathomorphological conclusion. The primary endpoint was a decrease in the Ki-67% level (a surrogate marker for the effectiveness of hormone therapy), the secondary endpoints were the objective response, a pathological response in the tumor and lymph nodes, and the quality of life. Results. In all patients (n = 54), the frequency of decrease Ki-67 level and the frequency of objective response were 57% and 50%, respectively. At the same time, the incidence of Ki-67% level decrease in the «toremifene» group was 42%, in the «toremifene+MLT» group - 56%, in the «toremifene+MTF» group - 74%. Multifactor analysis showed that the addition of MTF to toremifene increases the chances of reducing Ki-67 compared with control 4.2 times (RR 4.23 [95% CI 1,04417,139], p = 0.043). It is important that only in the patients of the «toremifene+MTF» group a significant correlation was found between the Ki-67 index decrease in the tumor and the BMI value above the norm (p = 0.015). A complete pathomorphological response in the tumor and lymph nodes was not achieved in any patient. The objective response in the study groups was 31.6%, 86.7% and 47.3%, respectively. The addition of MLT to hormone therapy with toremifene significantly increased the frequency of the objective response from 31.6% to 86.7% (x2 = 10.32, p = 0.001). The inclusion into neoadjuvant hormone therapy with toremifene of MLT or MTF did not reduce the quality of life of patients, while in 50% of patients in the «toremifene+MLT» group there was an improvement in sleep.
The aim of the study was to evaluate a 3-year distant treatment outcomes of patients with early breast cancer who had undergone sentinel lymph node biopsy. Methods. A total of 681 patients with early cT1-2N0M0 breast cancer treated in the N.N. Petrov research institute of oncology form 2012 till 2016 were retrospectively enrolled in the study. Radioisotopes were used to identify sentinel nodes. In case a macrometastatic lesion was found (>2mm) ALND was performed. Subsequent adequate systemic treatment and radiotherapy were administered in accordance with the pTNM status, biologic subtype and age. Results. A 3-year overall survival equaled 99.3% (SE 0.4%), recurrence-free survival was 99.2% (SE 0.4%). Survival of patients without nodal involvement reached 100%, whereas for patients with metastatic nodes it was 97.4% (SE 1.8%). The threshold for the number of the affected nodes significantly influencing survival equaled 1 (р=0,0187). Overall survival of patients with 0 to 1 positive lymph nodes was 99.7% (SE 0.3%), with more than 1 node involved - 95.7% (SE 0.3%) (р=0,00444). Conclusion. Overall 3-year survival of patients with early breast cancer approaches 100%. Sentinel lymph node biopsy allows avoiding unnecessary and traumatizing axillary dissection and improves the quality of life.
5 May 2017 in Tumors of female reproductive system
The article presents a literature review on late radiation injury (RI) of skin and subcutaneous fat after surgical treatment and radiation therapy (RT) in patients with breast cancer (BC). In Russia, the rate of radiation injuries in patients after RT exceeds 10–15 %. Combination treatment of BC (surgery and radiation) carries a risk of RI of skin and subcutaneous fat which might lead to dystrophic changes in the form of prominent radiation-induced fibrosis of the irradiated area, lower the quality of life, cause suffering and even death. Most of BC patients are of working age, so the problem of local RI is of social importance, and it requires effective methods of treatment and rehabilitation allowing for favorable conditions for patients’ social adaptation. Currently, there’s no consensus on the mechanisms of development of skin and subcutaneous fat late RI, and it’s being considered from several angles. Therefore, problems of determination of individual sensitivity to ionizing radiation and further study of local RI of skin and subcutaneous fat after surgical treatment and RT in BC patients are of utmost importance.